Submit Database Entry
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborumorem.
| Sponsor | Therapeutic Area/Condition | Medical Product Name | Trial Phase | Endpoint Position | Endpoint Type | PRO Measures/Assessments | PRO-based endpoint | %Participants using BYOD | Countries | Clinicaltrials.gov Identifier | Approving Regulatory Agencies | Label/Package Insert Link | Approved(y/n) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFIZER | COVID-19 | COMIRATY | III | Primary | Safety | Solicited local and system reaction diary | % of participants reporting the following for 7 days after Doses 1, 2, and 3: pain, redness, and swelling at injection site, fatigue, headache, muscle pain, chills, joint pain, fever, vomiting, diarrhea | 79% | USA | NCT04713553 | FDA, EMA | https://www.fda.gov/media/151707/download | y |
| Bayer | COVID-19 | test | https://fda.gov | y | |||||||||
| Otsuka | teest | test | testtl | y | |||||||||
| Takeda | test | https://fdsdsf | y | ||||||||||
| abbvie | test | Secondary | Efficacy | dsdsfdf | y | ||||||||
| Biogen | https://fda.gov | y | |||||||||||
| UK Pharma | COPD | Stuffinnit | 3 | Secondary | Diary | Reduction | 80 | UK | N/A | EMA | N/A | y | |
| Roche | MS | MS cure | Phase 3 | Primary | 78 | dsds | adsas | dsds | dsds | n | |||
| Sp1 | ther_cond | medprod | Phase 2a | Secondary, Tertiary | Safety | prom | prob | 45 | USA, Germany | ger | sdd | https://www.fda.gov/media/151707/download | y |
| Sp1 | ther_cond | medprod | Phase 2a | Secondary, Tertiary | Safety | Sp1 | prob | 45 | USA, Germany | ger | dfd | https://www.fda.gov/media/151707/download | y |
| Sp1 | ther_cond | medprod | Phase 2a | Secondary, Tertiary | Safety | Sp1 | prob | 45 | USA, Germany | ger | fdd | https://www.fda.gov/media/151707/download | y |